RRG001

Shanghai Refreshgene Technology Co., Ltd. · Phase 1 active Small molecule

At a glance

Generic name	RRG001
Sponsor	Shanghai Refreshgene Technology Co., Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety and Efficacy of RRG001 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD) (PHASE1, PHASE2)
The Preliminary Safety and Efficacy of RRG001 After Vitrectomy in Subjects With Proliferative Diabetic Retinopathy (PDR) (EARLY_PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

RRG001 CI brief — competitive landscape report
RRG001 updates RSS · CI watch RSS
Shanghai Refreshgene Technology Co., Ltd. portfolio CI